Novartis to make Leqvio for U.S. in Austria to overcome FDA delay

Novartis (NOVN.S) will manufacture anti-cholesterol drug Leqvio at its own plant in Austria to supply the United States as it seeks U.S. approval that has been delayed by regulatory concerns over a contractor's Italian facility.